Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Postoperative Pain
Interventions: TLC590, Liposomal Bupivacaine, Saline Placebo; Drug
Lead sponsor: TLC Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Bellaire, Texas • Houston, Texas + 1 more

Conditions: Huntington's Disease
Interventions: Creatine Monohydrate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 38
States / cities: Birmingham, Alabama • Irvine, California • Sacramento, California + 35 more

Conditions: Leukemia
Interventions: aldesleukin, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Male Factor Infertility, Female Factor Infertility
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Unequal Length of Limbs; Congenital, Lower Extremity Deformities, Congenital
Interventions: Botulinum toxin A injection, saline injection; Drug
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 5 Years to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 4
States / cities: Wilmington, Delaware • Honolulu, Hawaii • Portland, Oregon + 1 more

Conditions: Vaginosis, Bacterial, Premature Birth, Birth Weight, Chorioamnionitis
Interventions: oral versus vaginal metronidazole; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 16 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure
Interventions: Ruxolitinib; Drug
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 12 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Aurora, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more

Conditions: Huntington Disease
Interventions: lumbar puncture; Diagnostic Test
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 20 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Genetic Diseases, Inborn
Interventions: Sequence; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 1 Day and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Hirschsprung Disease, Enterocolitis
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 1 Day to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: X-Linked Hypophosphatemia
Interventions: Burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 1 Year to 4 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • Indianapolis, Indiana • St Louis, Missouri

Conditions: Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions: Not listed
Lead sponsor: Bastyr University; Other
Eligibility: 19 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions: becatecarin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: Soquelitinib, Placebo; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 12 more

Conditions: Electronic Fetal Monitoring, Fetal Hypoxia, Fetal-Placental Circulation
Interventions: Room air, 10L Oxygen by nonrebreather mask; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Primary Hyperoxaluria Type 1 (PH1)
Interventions: Placebo, Lumasiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 5
States / cities: San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Interventions: Lumbar Puncture, Blood Collection; Procedure
Lead sponsor: Biogen; Industry
Eligibility: Up to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Photoaging, Weight Loss, Skin Laxity, Photodamaged Skin, Volume Deficiency of the Midface
Interventions: Sculptra treatment, Restylane Treatment; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI
Interventions: Enzyme testing; Other
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Klinefelter Syndrome
Interventions: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 90 Days · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Brain Disorders, Birth Defects, Craniofacial Differences
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: CLN6, Batten Disease
Interventions: AT-GTX-501; Genetic
Lead sponsor: Emily de los Reyes; Other
Eligibility: 12 Months and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hemophilia A
Interventions: ReFacto; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 6 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more

Search by objective public record fields.

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

The Clinical Study of Sex Chromosome Variants

Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery

Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Mitochondrial Biomarkers in Huntington's Disease

Whole Genome Sequencing in the Neonatal Intensive Care Unit

Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Modifiable Variables in Parkinsonism (MVP)

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Angelman Syndrome (AS) Biomarker Study

Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies

Validating Pain Scales in Children and Young Adults

Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

Study on Moebius Syndrome and Congenital Facial Weakness Disorders

Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery